Axogen (AXGN) insider sale: 14,937 shares ($267K)
Axogen, Inc. insider filing shows a proposed sale of 14,937 common shares, with an aggregate market value of $267,073.56, through Morgan Stanley Smith Barney LLC on 10/03/2025.
Rhea-AI Filing Summary
Axogen, Inc. insider filing shows a proposed sale of 14,937 common shares, with an aggregate market value of $267,073.56, through Morgan Stanley Smith Barney LLC on 10/03/2025. The shares were acquired as Restricted Stock Units on 09/01/2024. The filer declares no undisclosed material information and notes reliance on Rule 144 and any applicable 10b5-1 trading plan mechanics. The notice also reports recent sales on 10/02/2025 totaling 10,020 shares for gross proceeds of $180,424.04 executed under a 10b5-1 program and an irrevocable trust.
Positive
- 14,937 shares identified for sale are explicitly from Restricted Stock Units acquired on 09/01/2024
- Sale to be routed through a major broker: Morgan Stanley Smith Barney LLC, providing execution transparency
- Filer attests to no undisclosed material information and references reliance on Rule 10b5-1 mechanics
Negative
- Insider sold 7,620 and 2,400 shares on 10/02/2025 for combined gross proceeds of $180,424.04, indicating continued insider selling
- Proposed sale of 14,937 shares represents incremental supply in the market on 10/03/2025
Insights
TL;DR: Insider proposes to sell 14,937 shares on 10/03/2025; prior sales of 10,020 shares occurred on 10/02/2025.
The filing discloses a planned sale of 14,937 common shares valued at $267,073.56 via Morgan Stanley Smith Barney LLC. These shares were granted as Restricted Stock Units on 09/01/2024, indicating the transaction relates to vested compensation rather than open-market purchases.
The schedule also records recent 10b5-1 sales and a trust sale totaling 10,020 shares for $180,424.04 on 10/02/2025, showing active disposition of shares over consecutive days. The filer affirms no undisclosed material information under the signature block.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Axogen (AXGN) report in this Form 144?
Were there any recent insider sales disclosed?
Through which broker will the proposed sale be executed?
Does the filer claim any undisclosed material information?
AI-generated analysis. How Rhea-AI works. Not financial advice.